Melane Sampson, Author at BioTuesdays

Developments

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

Atossa Therapeutics (NASDAQ:ATOS) announced that the USPTO has granted a new patent for enteric oral formulations comprising (Z)-endoxifen, including methods of treating patients. According to Atossa, the patent...

April 22, 2025

Developments

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Closely held PharmaJet announced it will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems at the World Vaccine Congress (WVC) on April 23, 2025 at 12:25 pm ET...

April 17, 2025

Feature

Arch advancing game-changing therapies for global kidney care

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

April 15, 2025

Developments

Ironwood reports updates on apraglutide following FDA interaction

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced that a confirmatory Phase 3 trial evaluating apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and dependence on parenteral support, is a requirement...

April 14, 2025

Executive Moves

Verano names Richard Tarapchak as CFO

Verano Holdings (Cboe CA:VRNO; OTCQX:VRNOF) announced that it has promoted Richard Tarapchak to chief financial officer (CFO), succeeding Brett Summerer, who has resigned. Mr. Tarapchak brings more than 30 years of...

April 14, 2025

Developments

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced the initiation of its first U.S.-based Phase 1/2a trial of CMND-100 in alcohol use disorder (AUD) at the Johns Hopkins University School of Medicine. According to...

April 11, 2025

Executive Moves

Healthcare Integrated Technologies appoints Anand Ijju as CTO

Healthcare Integrated Technologies (OTC PINK: HITC) announced the appointment of Anand Ijju as chief technology officer (CTO). Mr. Ijju brings extensive experience in scaling global technology ventures, complemented by...

April 10, 2025

Developments

ARPA-H grants Ginkgo and partners $29M to advance distributed manufacturing of medicines using grain

Ginkgo Bioworks (NYSE:DNA) announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H) and partners—Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by...

April 10, 2025

Developments

FDA grants three FTDs for Allogene’s ALLO-329

Allogene Therapeutics (NASDAQ:ALLO) announced that the FDA has granted three fast track designations (FTDs) for its ALLO-329, a next-generation dual-target CD19/CD70 allogeneic CAR T for the treatment of lupus...

April 8, 2025

Executive Moves

Telo appoints John Farlinger to BOD

Telo Genomics (TSXV:TELO) announced the appointment of John Farlinger to its board of directors (BOD) and will serve as chair of the company’s audit committee. With more than 30 years of experience in telecom...

April 4, 2025

Author - Melane Sampson

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Arch advancing game-changing therapies for global kidney care

Ironwood reports updates on apraglutide following FDA interaction

Verano names Richard Tarapchak as CFO

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Healthcare Integrated Technologies appoints Anand Ijju as CTO

ARPA-H grants Ginkgo and partners $29M to advance distributed manufacturing of medicines using grain

FDA grants three FTDs for Allogene’s ALLO-329

Telo appoints John Farlinger to BOD

Subscribe